查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604758

自體細胞治療市場：按來源、適應症和最終用戶分類 - 2025-2030 年全球預測

Autologous Cell Therapies Market by Source (Bone Marrow, Chondrocytes, Epidermis), Indication (Autoimmune Disorders, Cancer, Cardiovascular Disorders), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

自體細胞治療市場2023年估值為81.1億美元，預計2024年將達到92.4億美元，複合年成長率為14.52%，到2030年將達到209.6億美元。

自體細胞療法涉及使用患者自身的細胞來治療或再生組織或器官，主要用於個人化醫療。對此類治療的需求正在增加，因為它們有可能最大限度地減少免疫排斥並改善癌症、心血管疾病和神經退化性疾病等疾病的結果。其應用範圍廣泛，包括再生醫學、癌症治療、整形外科治療等。最終用途多種多樣，包括醫院、診所和研究機構，個人化和精準醫療日益成為優先事項。市場成長是由細胞研究的進步、慢性病盛行率的上升以及對細胞行為和操作的了解的加深所推動的，這些都為馬蘇的治療開闢了新的途徑。人工智慧和機器學習在預測性患者結果分析中的整合將進一步增加市場興趣。儘管有這些機遇，但諸如高成本、細胞處理的物流問題、監管障礙和缺乏標準化治療通訊協定等挑戰仍然是主要限制因素。對基因操縱和大規模生產的複雜性的道德擔憂也阻礙了市場的無縫擴張。對於公司而言，投資於可擴展製造流程的研發和改進低溫保存技術可以釋放新的可能性。用於高效細胞處理和增強生物資訊工具的自動化和機器人技術創新可以提供競爭優勢。促進生物技術公司、學術機構和醫療保健提供者之間的合作也可以促進從研究到臨床應用的順利過渡。自體細胞治療市場的本質是動態且分散的，趨勢表明對客製化和針對患者的解決方案的需求迅速成長。透過專注於這些創新和協作領域，公司可以克服挑戰並利用這一變革時期生物技術領域的新興機會。

主要市場統計
基準年[2023] 81.1億美元
預計年份 [2024] 92.4億美元
預測年份 [2030] 209.6億美元
複合年成長率（%） 14.52%

市場動態：揭示快速發展的自體細胞治療市場的關鍵市場洞察

自體細胞治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 世界各地慢性病的增加
    • 越來越重視新用途的藥物開發
    • 隨著醫療基礎設施的改善，對個人化藥物的需求不斷增加
  • 市場限制因素
    • 自體細胞療法相關的高成本
  • 市場機會
    • 自體細胞療法生產分散化的技術進步
    • 政府增加細胞研究的投資
  • 市場挑戰
    • 交貨時間長和保存期限有限的問題

波特五力：駕馭自體細胞治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解自體細胞治療市場的外在影響

外部宏觀環境因素在塑造自體細胞治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解自體細胞治療市場的競爭狀況

自體細胞治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣自體細胞治療市場供應商績效評估

FPNV定位矩陣是評估自體細胞治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了自體細胞治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，自體細胞治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地慢性病的發生率正在上升
      • 擴大對新應用藥物開發的關注
      • 隨著醫療基礎設施的改善，對個人化醫療的需求不斷增加。
    • 抑制因素
      • 自體細胞療法相關的高成本
    • 機會
      • 自體細胞療法製造分散化的技術進步
      • 政府增加細胞研究的投資
    • 任務
      • 與處理時間長和保留期限有限相關的問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章自體細胞治療市場：依來源分類

  • 骨髓
  • 軟骨細胞
  • 表皮
  • 造血幹細胞
  • 間質幹細胞

第7章 自體細胞治療市場（按適應症）

  • 自體免疫疾病
  • 癌症
  • 心血管疾病
  • 神經退化性疾病
  • 整形外科
  • 傷口癒合

第8章自體細胞治療市場：依最終使用者分類

  • 學術研究機構
  • 門診手術中心
  • 醫院/診所

第9章 美洲自體細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區自體細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲自體細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議

公司名單

  • Abata Therapeutics
  • Achilles Therapeutics plc
  • Adaptimmune Therapeutics PLC
  • Adicet Bio Inc.
  • AIVITA Biomedical, Inc.
  • Aspen Neuroscienc Inc.
  • Bellicum Phamaceuticals, Inc.
  • BioLineRx Ltd.
  • BioSpace, Inc.
  • BrainStorm Cell Limited.
  • Bristol-Myers Squibb Company
  • Carisma Therapeutics Inc.
  • Catalent, Inc.
  • Cell Therapy Catapult Ltd.
  • Fate Therapeutics Inc.
  • GentiBio, Inc.
  • IASO BioTherapeutics
  • Kyverna Therapeutics, Inc.
  • NOVADIP Biosciences SA
  • Orchard Therapeutics Inc.
  • T-knife Therapeutics, Inc.
  • ThermoGenesis Holdings, Inc.
  • Triumvira Immunologics Inc.
  • Vita Therapeutics, Inc.
Product Code: MRR-69324464D299

The Autologous Cell Therapies Market was valued at USD 8.11 billion in 2023, expected to reach USD 9.24 billion in 2024, and is projected to grow at a CAGR of 14.52%, to USD 20.96 billion by 2030.

Autologous Cell Therapies involve using a patient's own cells for the treatment and regeneration of tissues and organs, primarily in personalized medicine. The necessity for these therapies grows from their potential to minimize immune rejection and improve treatment outcomes for conditions like cancer, cardiovascular disorders, and neurodegenerative diseases. Their application spans across regenerative medicine, cancer therapies, orthopedic treatments, and beyond. The end-use scope is significant across hospitals, clinics, and research institutes, where personalized and precision medicine is increasingly prioritized. Market growth is driven by advancements in cell-based research, escalating prevalence of chronic diseases, and an enhanced understanding of cell behavior and manipulation, which open up innovative pathways for treatment. The integration of AI and machine learning in predictive analytics for patient outcomes further propels market interest. Despite these opportunities, challenges such as high costs, logistical issues with cell processing, regulatory hurdles, and a lack of standardized treatment protocols pose significant limitations. Ethical concerns about genetic manipulation and complexities in large-scale production also deter seamless market expansion. For businesses, investing in R&D for scalable manufacturing processes and improving cryopreservation techniques can unlock new possibilities. Innovations in automation and robotics for efficient cell handling and augmentation of bioinformatics tools could offer competitive advantages. Encouraging collaborations between biotech firms, academic institutions, and healthcare providers can also facilitate smoother transitions from research to clinical applications. The nature of the autologous cell therapy market is dynamic and segmented, with trends indicating a surging demand for customization and patient-specific solutions. By focusing on these areas of innovation and collaboration, companies can better position themselves to navigate challenges and capitalize on the burgeoning opportunities within this transformative sector of biotechnology.

KEY MARKET STATISTICS
Base Year [2023] USD 8.11 billion
Estimated Year [2024] USD 9.24 billion
Forecast Year [2030] USD 20.96 billion
CAGR (%) 14.52%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autologous Cell Therapies Market

The Autologous Cell Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in incidences of chronic diseases worldwide
    • Expanding focus on drug development for new applications
    • Growing need for personalized medicines with improving healthcare infrastructure
  • Market Restraints
    • High cost associated with autologous cell therapy
  • Market Opportunities
    • Technological advancements for decentralizing manufacturing of autologous cell therapy
    • Rising government investments in cell-based research
  • Market Challenges
    • Problems associated with long turnaround time and limited shelf life

Porter's Five Forces: A Strategic Tool for Navigating the Autologous Cell Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autologous Cell Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autologous Cell Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autologous Cell Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autologous Cell Therapies Market

A detailed market share analysis in the Autologous Cell Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autologous Cell Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autologous Cell Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autologous Cell Therapies Market

A strategic analysis of the Autologous Cell Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autologous Cell Therapies Market, highlighting leading vendors and their innovative profiles. These include Abata Therapeutics, Achilles Therapeutics plc, Adaptimmune Therapeutics PLC, Adicet Bio Inc., AIVITA Biomedical, Inc., Aspen Neuroscienc Inc., Bellicum Phamaceuticals, Inc., BioLineRx Ltd., BioSpace, Inc., BrainStorm Cell Limited., Bristol-Myers Squibb Company, Carisma Therapeutics Inc., Catalent, Inc., Cell Therapy Catapult Ltd., Fate Therapeutics Inc., GentiBio, Inc., IASO BioTherapeutics, Kyverna Therapeutics, Inc., NOVADIP Biosciences S.A., Orchard Therapeutics Inc., T-knife Therapeutics, Inc., ThermoGenesis Holdings, Inc., Triumvira Immunologics Inc., and Vita Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Autologous Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Bone Marrow, Chondrocytes, Epidermis, Haematopoietic Stem Cells, and Mesenchymal Stem Cells.
  • Based on Indication, market is studied across Autoimmune Disorders, Cancer, Cardiovascular Disorders, Neurodegenerative Disorders, Orthopedics, and Wound Healing.
  • Based on End-User, market is studied across Academics & Research Institutes, Ambulatory Surgical Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in incidences of chronic diseases worldwide
      • 5.1.1.2. Expanding focus on drug development for new applications
      • 5.1.1.3. Growing need for personalized medicines with improving healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with autologous cell therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements for decentralizing manufacturing of autologous cell therapy
      • 5.1.3.2. Rising government investments in cell-based research
    • 5.1.4. Challenges
      • 5.1.4.1. Problems associated with long turnaround time and limited shelf life
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autologous Cell Therapies Market, by Source

  • 6.1. Introduction
  • 6.2. Bone Marrow
  • 6.3. Chondrocytes
  • 6.4. Epidermis
  • 6.5. Haematopoietic Stem Cells
  • 6.6. Mesenchymal Stem Cells

7. Autologous Cell Therapies Market, by Indication

  • 7.1. Introduction
  • 7.2. Autoimmune Disorders
  • 7.3. Cancer
  • 7.4. Cardiovascular Disorders
  • 7.5. Neurodegenerative Disorders
  • 7.6. Orthopedics
  • 7.7. Wound Healing

8. Autologous Cell Therapies Market, by End-User

  • 8.1. Introduction
  • 8.2. Academics & Research Institutes
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Hospitals & Clinics

9. Americas Autologous Cell Therapies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autologous Cell Therapies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autologous Cell Therapies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abata Therapeutics
  • 2. Achilles Therapeutics plc
  • 3. Adaptimmune Therapeutics PLC
  • 4. Adicet Bio Inc.
  • 5. AIVITA Biomedical, Inc.
  • 6. Aspen Neuroscienc Inc.
  • 7. Bellicum Phamaceuticals, Inc.
  • 8. BioLineRx Ltd.
  • 9. BioSpace, Inc.
  • 10. BrainStorm Cell Limited.
  • 11. Bristol-Myers Squibb Company
  • 12. Carisma Therapeutics Inc.
  • 13. Catalent, Inc.
  • 14. Cell Therapy Catapult Ltd.
  • 15. Fate Therapeutics Inc.
  • 16. GentiBio, Inc.
  • 17. IASO BioTherapeutics
  • 18. Kyverna Therapeutics, Inc.
  • 19. NOVADIP Biosciences S.A.
  • 20. Orchard Therapeutics Inc.
  • 21. T-knife Therapeutics, Inc.
  • 22. ThermoGenesis Holdings, Inc.
  • 23. Triumvira Immunologics Inc.
  • 24. Vita Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. AUTOLOGOUS CELL THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTOLOGOUS CELL THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOLOGOUS CELL THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CHONDROCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY EPIDERMIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HAEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023